Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 3/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.43 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3866048 | 1.00 | SIGMAR1 (0.48) | SIGMAR1ACACBNQO1SLC5A1SLC5A2 | |
| SCHEMBL2247026 | 0.82 | SIGMAR1 (0.44) | SIGMAR1ACACBNQO1SLC5A1SLC5A2 | |
| SCHEMBL4248652 | 0.78 | NQO1 (0.67) | SIGMAR1ACACBNQO1SLC5A1SLC5A2 | |
| SCHEMBL12548935 | 0.78 | ACACB (0.44) | SIGMAR1ACACBNQO1SLC5A1SLC5A2 | |
| SCHEMBL27028893 | 0.78 | S1PR2 (0.49) | SIGMAR1ACACBSLC5A1SLC5A2NPC1 | |
| SCHEMBL27130219 | 0.78 | S1PR2 (0.49) | SIGMAR1ACACBSLC5A1SLC5A2NPC1 | |
| SCHEMBL2247027 | 0.78 | SIGMAR1 (0.43) | SIGMAR1ACACBNQO1SLC5A1SLC5A2 | |
| SCHEMBL7866257 | 0.77 | SIGMAR1 (0.50) | SIGMAR1ACACBNQO1MAPTLMNA | |
| SCHEMBL29466896 | 0.77 | SIGMAR1 (0.50) | SIGMAR1ACACBNQO1MAPTLMNA | |
| SCHEMBL10575040 | 0.77 | NQO1 (0.64) | SIGMAR1NQO1SLC5A1SLC5A2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
| US-7786121-B2 | Derivatives of hydroxamic acid as metalloproteinase inhibitors | VERNALIS (OXFORD) LIMITED (GB) | 2010-08-31 | — | — | US | disclosed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | SIGMAR1 594/4885ACACB 2908/4885NQO1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.